Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial
Journal of Clinical Oncology · 20.12.2023 · 41 (36) · 5512-5523
DOI: 10.1200/jco.22.01862 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.12.2023. Verfasst von Constantin Roder und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Tübingen, Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Eberhard-Karls-U…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Prospective data suggested a superiority of intraoperative MRI (iMRI) over 5-aminolevulinic acid (5-ALA) for achieving complete resections of contrast enhancement in glioblastoma surgery. We investigated this hypothesis in a prospective clinical trial and correlated residual disease volumes with clinical outcome in newly diagnosed glioblastoma. METHODS This is a prospective controlled multicenter parallel-group trial with two center-specific treatment arms (5-ALA and iMRI) and blinded evaluation. The primary end point was complete resection of contrast enhancement on early postoperative MRI. We assessed resectability and extent of resection by an independent blinded centralized review of preoperative and postoperative MRI with 1-mm slices. Secondary end points included progression-free survival (PFS) and overall survival (OS), patient-reported quality of life, and clinical parameters. RESULTS We recruited 314 patients with newly diagnosed glioblastomas at 11 German centers. A total of 127 patients in the 5-ALA and 150 in the iMRI arm were analyzed in the as-treated analysis. Complete resections, defined as a residual tumor ≤0.175 cm³, were achieved in 90 patients (78%) in the 5-ALA and 115 (81%) in the iMRI arm ( P = .79). Incision-suture times ( P < .001) were significantly longer in the iMRI arm (316 v 215 [5-ALA] minutes). Median PFS and OS were comparable in both arms. The lack of any residual contrast enhancing tumor (0 cm³) was a significant favorable prognostic factor for PFS ( P < .001) and OS ( P = .048), especially in methylguanine-DNA-methyltransferase unmethylated tumors ( P = .006). CONCLUSION We could not confirm superiority of iMRI over 5-ALA for achieving complete resections. Neurosurgical interventions in newly diagnosed glioblastoma shall aim for safe complete resections with 0 cm³ contrast-enhancing residual disease, as any other residual tumor volume is a negative predictor for PFS and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, University Hospital Tübingen, Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Eberhard-Karls-University, Tübingen, Germany.
- Department of Neurosurgery, University Hospital Münster, Westphalian-Wilhelms-University, Münster, Germany.
- Department of Neurosurgery, University Hospital Ulm/Günzburg, University of Ulm, Günzburg, Germany.
- Department of Neurosurgery, University Hospital Heidelberg, Rupprecht-Karls-University, Heidelberg, Germany.
- Department of Neurosurgery, University Hospital Göttingen, Georg-August-University, Göttingen, Germany.
- Department of Neurosurgery, Johanniter Hospital Bonn, Bonn, Germany.
ORCID-Profile: Constantin Roder, Jan Coburger, Moritz Scherer, Patrick Haas, Marcel Alexander Kamp, Marco Skardelly, Torben Scholz, Florian Stockhammer, Ghazaleh Tabatabai, Peter Martus, Sotirios Bisdas, Oliver Ganslandt, Christian Rainer Wirtz
Zitieren
APA
Roder, C., Stummer, W., Coburger, J., Scherer, M., Haas, P., von der Brelie, C., Kamp, M. A., Löhr, M., Hamisch, C. A., Skardelly, M., Scholz, T., Schipmann, S., Rathert, J., Brand, C. M., Pala, A., Ernemann, U., Stockhammer, F., Gerlach, R., Kremer, P., …, & Tatagiba, M. (2023). Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. Journal of Clinical Oncology, 41(36), 5512-5523. https://doi.org/10.1200/jco.22.01862
Vancouver
Roder C, Stummer W, Coburger J, Scherer M, Haas P, von der Brelie C, et al. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. Journal of Clinical Oncology. 2023;41(36):5512-5523. doi:10.1200/jco.22.01862
BibTeX
@article{Roder2023,
author = {Roder, Constantin and Stummer, Walter and Coburger, Jan and Scherer, Moritz and Haas, Patrick and von der Brelie, Christian and Kamp, Marcel Alexander and Löhr, Mario and Hamisch, Christina A and Skardelly, Marco and Scholz, Torben and Schipmann, Stephanie and Rathert, Julian and Brand, Catrin Marlene and Pala, Andrej and Ernemann, Ulrike and Stockhammer, Florian and Gerlach, Rüdiger and Kremer, Paul and Goldbrunner, Roland and Ernestus, Ralf-Ingo and Sabel, Michael and Rohde, Veit and Tabatabai, Ghazaleh and Martus, Peter and Bisdas, Sotirios and Ganslandt, Oliver and Unterberg, Andreas and Wirtz, Christian Rainer and Tatagiba, Marcos},
title = {Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {36},
pages = {5512--5523},
doi = {10.1200/jco.22.01862}
}
EUVIMED